Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study
Table 4
Change in intensity of symptoms from baseline to each visit for patients from the effectiveness population who underwent radiotherapy or a TURP.
At baseline ( = 53)
Mild symptoms
Moderate symptoms
Severe symptoms
At week 24 ( = 46)
( = 0.017* versus baseline)
No symptoms
1 (2.2%)
0 (0%)
0 (0%)
Mild symptoms
14 (30.4%)
9 (19.6%)
1 (2.2%)
Moderate symptoms
1 (2.2%)
16 (34.8%)
0 (0%)
Severe symptoms
1 (2.2%)
1 (2.2%)
2 (4.3%)
At week 48 ( = 49)
( = 0.027* versus baseline)
No symptoms
2 (4.1%)
0 (0%)
0 (0%)
Mild symptoms
15 (30.6%)
12 (24.5%)
0 (0%)
Moderate symptoms
3 (6.1%)
13 (26.5%)
2 (4.1%)
Severe symptoms
0 (0%)
1 (2.0%)
1 (2.0%)
At last available visit ( = 53)
( = 0.005* versus baseline)
No symptoms
2 (3.8%)
0 (0%)
0 (0%)
Mild symptoms
15 (28.3%)
14 (26.4%)
1 (1.9%)
Moderate symptoms
3 (5.7%)
14 (26.4%)
2 (3.8%)
Severe symptoms
0 (0%)
1 (1.9%)
1 (1.9%)
Bhapkar’s test for homogeneity. Note: percentages are based on the number of patients with available responses. To operate Bhapkar’s test, a frequency equal to 0 was replaced by 0.001.
